{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:05:01Z","timestamp":1775747101994,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00432-022-03931-4","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T15:02:48Z","timestamp":1645801368000},"page":"1269-1273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: a case report"],"prefix":"10.1007","volume":"148","author":[{"given":"Qi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingzhi","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-3244","authenticated-orcid":false,"given":"Liyun","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"3931_CR1","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s11523-021-00843-0","volume":"16","author":"ZT Al-Salama","year":"2021","unstructured":"Al-Salama ZT (2021) Durvalumab: a review in extensive-stage SCLC. Targ Oncol 16:857\u2013864. https:\/\/doi.org\/10.1007\/s11523-021-00843-0","journal-title":"Targ Oncol"},{"key":"3931_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","volume":"5","author":"P Danaher","year":"2017","unstructured":"Danaher P, Warren S, Dennis L et al (2017) Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer 5:18. https:\/\/doi.org\/10.1186\/s40425-017-0215-8","journal-title":"J Immunother Cancer"},{"key":"3931_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat7807","volume":"10","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Chan TA, Kroemer G et al (2018) The hallmarks of successful anticancer immunotherapy. Sci Transl Med 10:eaat7807. https:\/\/doi.org\/10.1126\/scitranslmed.aat7807","journal-title":"Sci Transl Med"},{"key":"3931_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y et al (2021) Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 22:51\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30539-8","journal-title":"Lancet Oncol"},{"key":"3931_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100889","volume":"14","author":"W Huang","year":"2021","unstructured":"Huang W, Chen J-J, Xing R, Zeng Y-C (2021) Combination therapy: future directions of immunotherapy in small cell lung cancer. Transl Oncol 14:100889. https:\/\/doi.org\/10.1016\/j.tranon.2020.100889","journal-title":"Transl Oncol"},{"key":"3931_CR6","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1172\/JCI121323","volume":"129","author":"P Kellish","year":"2019","unstructured":"Kellish P, Shabashvili D, Rahman MM et al (2019) Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival. J Clin Investig 129:2279\u20132292. https:\/\/doi.org\/10.1172\/JCI121323","journal-title":"J Clin Investig"},{"key":"3931_CR7","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534\u2013e542. https:\/\/doi.org\/10.1016\/S1470-2045(15)00088-1","journal-title":"Lancet Oncol"},{"key":"3931_CR8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I et al (2017) Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170:1109-1119.e10. https:\/\/doi.org\/10.1016\/j.cell.2017.08.027","journal-title":"Cell"},{"key":"3931_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jtho.2019.09.083","volume":"15","author":"EL Schenk","year":"2020","unstructured":"Schenk EL, Mandrekar SJ, Dy GK et al (2020) A randomized double-blind phase ii study of the seneca valley virus (NTX-010) versus Placebo for patients with extensive-stage SCLC (ES SCLC) who were stable or responding after at least four cycles of platinum-based chemotherapy: north central cancer treatment group (Alliance) N0923 study. J Thorac Oncol 15:110\u2013119. https:\/\/doi.org\/10.1016\/j.jtho.2019.09.083","journal-title":"J Thorac Oncol"},{"key":"3931_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA A Cancer J Clin 71:7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"CA A Cancer J Clin"},{"key":"3931_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.omto.2019.04.003","volume":"13","author":"V Sivanandam","year":"2019","unstructured":"Sivanandam V, LaRocca CJ, Chen NG et al (2019) Oncolytic viruses and immune checkpoint inhibition: the best of both worlds. Mol Ther-Oncolytics 13:93\u2013106. https:\/\/doi.org\/10.1016\/j.omto.2019.04.003","journal-title":"Mol Ther-Oncolytics"},{"key":"3931_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13947","volume":"1759\u20137714","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Li Y, Zhao Q et al (2021) Recombinant human adenovirus type 5 (Oncorine) reverses resistance to immune checkpoint inhibitor in a patient with recurrent non-small cell lung cancer: a case report. Thorac Cancer 1759\u20137714:13947. https:\/\/doi.org\/10.1111\/1759-7714.13947","journal-title":"Thorac Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-03931-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-03931-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-03931-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T07:32:04Z","timestamp":1650353524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-03931-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3931"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-03931-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"4 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Nanjing Drum Tower Hospital (No. 2020-143).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from the patient for participating and publication of this case.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}